US Patent

US11839599 — Methods of providing solriamfetol therapy to subjects with impaired renal function

Method of Use · Assigned to Axsome Malta Ltd · Expires 2040-03-19 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for providing solriamfetol therapy to subjects with impaired renal function, including optimized dose escalation and adjusted dosing.

USPTO Abstract

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3764 — solriamfetol-hydrochloride
U-3764 — solriamfetol-hydrochloride

Patent Metadata

Patent number
US11839599
Jurisdiction
US
Classification
Method of Use
Expires
2040-03-19
Drug substance claim
No
Drug product claim
No
Assignee
Axsome Malta Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.